跳至主要内容
临床试验/NCT01117155
NCT01117155撤回不适用

A Pilot Study Evaluating 18F-L-Thymidine (FLT) PET Imaging in Children With Gliomas

National Cancer Institute (NCI)0 个研究点开始时间: 2010年4月23日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回

研究概览

简要总结

Background:

  • Children with brain tumors often have magnetic resonance imaging (MRI) scans to see if the tumor has responded to therapy or to see if the tumor has grown. Sometimes, it is difficult to tell if the scan is abnormal because of tumor size or shape, swelling, scar tissue, or dead tissue. Because brain tumor biopsies require surgery, researchers are looking for more noninvasive ways of evaluating brain tumors.
  • Positron emission tomography (PET) scans use a radioactive sugar known as 18F-FDG to try to determine if a tumor is active or not. Active tumors generally take up more sugar than the surrounding tissue, but because normal brain tissue uses the same sugar as brain tumors, it is then difficult to tell if tumor tissue is taking up sugar or not. A different radioactive agent, 18F-FLT, is now being studied in some adults with different kinds of tumors. Researchers are interested in determining whether it is possible to use this agent as a marker of tumor activity in children.

Objectives:

  • To determine the safety and effectiveness of 18F-FLT for pediatric glioma scans.
  • To compare the results of 18F-FLT studies with studies using the radioactive agents 18F-FDG and 1H-MRSI.

Eligibility:

  • Children less than 18 years of age who are having radiation therapy to treat malignant gliomas.

Design:

  • Participants will have scanning tests before radiation therapy, 1 to 3 weeks after radiation therapy, and if researchers suspect that the tumor is growing.
  • This study will involve three separate imaging tests (1H-MRSI, 18F-FDG PET, and 18F-FLT PET).
  • Proton spectroscopy (1H-MRSI) is a procedure that is similar to MRI and is performed in the same scanner as an MRI. Because this scan is long (2-3 hours), most children will receive medications from an anesthesiologist so that they can sleep through the procedure.
  • Within 2 weeks of the 1H-MRSI scan, participants will have the PET scans with both the standard contrast agent (18F-FDG) and the experimental agent (18F-FLT). These scans will last approximately 1 hour each.

详细描述

BACKGROUND:

  • A limitation of current investigational therapy for patients with brain tumors is assessment of response.
  • (18)F-FDG PET is commonly used to assess tumor metabolism. However, normal brain uses glucose as an energy source, resulting in increased background FDG uptake, which confounds results and makes it difficult to distinguish normal from neoplastic activity.
  • Newer imaging techniques that noninvasively assess metabolic and physiologic characteristics of brain tumor tissue are being developed to identify biomarkers of clinical efficacy in trials of new molecularly targeted agents.
  • (18)F-fluorothymidine (FLT) is a PET radiopharmaceutical that is taken up by proliferating cells and may therefore serve as a surrogate marker of early response or lack of response to treatment.
  • This study will prospectively evaluate (18)F-FLT in children undergoing radiation therapy for gliomas.

OBJECTIVES:

Primary objectives:

  • Determine the feasibility of (18)F-FLT PET imaging in pediatric patients with malignant gliomas
  • Determine the ability of (18)F-FLT PET imaging to detect treatment changes in pediatric patients with malignant gliomas undergoing radiation therapy

研究设计

研究类型
Observational
时间视角
Prospective

入排标准

年龄范围
1 Year 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Nih

相似试验